Therapeutic compositions that produce an immune response
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-039/00
A61K-039/385
출원번호
US-0152698
(1998-09-02)
등록번호
US-7361346
(2008-04-22)
발명자
/ 주소
Madiyalakan,Ragupathy
Noujaim,Antoine A.
Baum,Richard P.
Schultes,Birgit
Leveugle,Beatrice
Kreutz,Fernando
출원인 / 주소
Altarex Corp.
대리인 / 주소
Ropes & Gray LLP
인용정보
피인용 횟수 :
0인용 특허 :
18
초록▼
The invention provides a method for stimulating the production of antibodies to a cryptic epitope on a soluble antigen by administering to a patient having such a cryptic epitope a binding agent that binds to the soluble antigen and forming a complex between the binding agent and the soluble antigen
The invention provides a method for stimulating the production of antibodies to a cryptic epitope on a soluble antigen by administering to a patient having such a cryptic epitope a binding agent that binds to the soluble antigen and forming a complex between the binding agent and the soluble antigen, wherein the cryptic epitope is exposed and the patient generates antibodies that bind to the cryptic epitope.
대표청구항▼
We claim: 1. A method of treating an oncological disease comprising stimulating a multi-epitopic immune response to a tumor-associated antigen comprising: administering to a host a complex formed from a soluble tumor-associated antigen and an antibody or antigen binding fragment thereof that binds
We claim: 1. A method of treating an oncological disease comprising stimulating a multi-epitopic immune response to a tumor-associated antigen comprising: administering to a host a complex formed from a soluble tumor-associated antigen and an antibody or antigen binding fragment thereof that binds to a first epitope of the tumor-associated antigen, wherein the tumor-associated antigen is CA 125, and wherein the administration of the complex induces host antibodies reactive with at least one other epitope of the tumor-associated antigen. 2. The method of claim 1, wherein the antibody is selected from the group consisting of a monoclonal antibody, a single chain antibody, a humanized antibody, and a chimeric antibody. 3. The method of claim 1, wherein the host is a human. 4. The method of claim 1, wherein the complex is administered with an adjuvant. 5. The method of claim 1, wherein the antibody or antigen binding fragment thereof of the complex is formulated at a dose of from about 0.1 μg to about 2 mg per kilogram of body weight of the host. 6. The method of claim 1, wherein the complex induces cytotoxic T cells reactive with the antigen. 7. The method of claim 1, wherein the antibody or antigen binding fragment thereof is formulated in the complex at a dose of about 2 mg per host. 8. The method of claim 1, wherein the antibody or antigen binding fragment thereof is formulated in the complex at a dose of from about 0.1 μg to about 200 μg per kilogram of body weight of the host. 9. The method of claim 1, wherein the antibody is produced by the hybridoma having ATCC deposit number PTA-1883. 10. A method of treating an oncological disease comprising stimulating a multi-epitopic immune response to a tumor-associated antigen comprising administering to a host a complex consisting essentially of a soluble tumor-associated antigen and an antibody or antigen binding fragment thereof that binds to a first epitope of the tumor-associated antigen, wherein said tumor-associated antigen is CA 125, and wherein the administration of the complex induces host antibodies and cytotoxic T cells reactive with the tumor-associated antigen. 11. The method of claim 10, wherein the antibody is produced by the hybridoma having ATCC deposit number PTA-1883. 12. A method of treating an oncological disease comprising stimulating a multi-epitopic immune response to a tumor-associated antigen comprising administering to a host a complex consisting essentially of a soluble tumor-associated antigen and an antibody or antigen binding fragment thereof that binds to a first epitope of the tumor-associated antigen, wherein said tumor-associated antigen is CA 125, and wherein the administration of the complex induces cytotoxic T cells reactive with the tumor-associated antigen. 13. The method of claim 12, wherein the complex further induces host antibodies reactive with at least one other epitope of the tumor-associated antigen. 14. The method of claim 12, wherein the antibody is produced by the hybridoma having ATCC deposit number PTA-1883. 15. A method of treating an oncological disease comprising administering to a host a complex formed from a soluble tumor-associated antigen and an antibody or antigen binding fragment thereof that binds to a first epitope of the tumor-associated antigen, wherein said tumor-associated antigen is CA 125, and wherein the administration of the complex induces host antibodies reactive with at least one other epitope of the tumor-associated antigen. 16. The method of claim 15, wherein the complex induces cytotoxic T cells reactive with the tumor-associated antigen. 17. The method of claim 15, wherein the complex induces host antibodies reactive with at least one other epitope of the antigen. 18. A method of treating an oncological disease comprising administering to a host a complex formed from a soluble tumor-associated antigen and an antibody or antigen binding fragment thereof that binds to a first epitope of the tumor-associated antigen, wherein said tumor-associated antigen is CA 125, and wherein the administration of the complex induces cytotoxic T cells reactive with the tumor-associated antigen. 19. A method of treating an oncological disease comprising stimulating a multi-epitopic immune response to a tumor-associated antigen comprising administering to a host a complex formed from a soluble tumor-associated antigen and an IgG antibody or antigen binding fragment thereof that binds to a first epitope of the tumor-associated antigen, wherein said tumor-associated antigen is CA 125, and wherein the administration of the complex induces host antibodies reactive with at least one other epitope of the tumor-associated antigen. 20. The method of claim 19, wherein the antibody is produced by the hybridoma having ATCC deposit number PTA-1883. 21. A method of treating an oncological disease comprising stimulating a multi-epitopic immune response to a tumor-associated antigen comprising administering to a host a complex formed from a soluble tumor-associated antigen and an IgG antibody or antigen binding fragment thereof that binds to a first epitope of the tumor-associated antigen, wherein said tumor-associated antigen is CA 125, and wherein the administration of the complex induces cytotoxic T cells reactive with the tumor-associated antigen. 22. The method of claim 21, wherein the antibody is produced by the hybridoma having ATCC deposit number PTA-1883. 23. The method of any of claims 1, 10, 12, 15, 18, 19, and 21, wherein the antibody is a non-human antibody. 24. The method of any of claims 1, 10, 12, 15, 18, 19, and 21, wherein said antibody or antigen binding fragment thereof comprises an Fc portion that binds an Fcγ RII receptor. 25. The method of any of claims 1, 10, 12, 15, 18, 19, and 21, wherein said antibody is an IgG1 antibody or an antigen-binding fragment thereof. 26. A method of treating an oncological disease comprising stimulating a multi-epitopic immune response to a tumor-associated antigen comprising: administering to a host a complex formed from a soluble tumor-associated antigen and an antibody or antigen binding fragment thereof that binds to a first epitope of the tumor-associated antigen, wherein the tumor-associated antigen is CA 125, and the first epitope of the tumor-associated antigen is the epitope bound by an antibody produced by the hybridoma having ATCC deposit number PTA-1883, and, wherein the administration of the complex induces host antibodies reactive with at least one other epitope of the tumor-associated antigen. 27. A composition suitable for administration to a host for altering immunogenicity of a tumor-associated antigen comprising a complex of a soluble tumor-associated antigen and an antibody or antigen binding fragment thereof that specifically binds to an epitope of the antigen, wherein said tumor-associated antigen is CA 125, and wherein administration of the composition to a host results in a multi-epitopic immune response including production of antibodies reactive with at least one other epitope of the tumor-associated antigen. 28. The composition of claim 27, wherein the antibody is selected from the group consisting a monoclonal antibody, a single chain antibody, a humanized antibody, and a chimeric antibody. 29. The composition of claim 27, wherein the antibody is a monoclonal antibody. 30. The composition of claim 27, wherein the host is a human. 31. A composition suitable for administration to a host for altering immunogenicity of a tumor-associated antigen comprising a complex of a soluble tumor-associated antigen and an IgG antibody or antigen binding fragment thereof that specifically binds to an epitope of the antigen, wherein said tumor-associated antigen is CA 125, and wherein administration of the composition to a host results in a multi-epitopic immune response including production of antibodies reactive with at least one other epitope of the tumor-associated antigen. 32. The composition of claim 27 or 31, wherein the antibody is a non-human antibody. 33. The composition of claim 27 or 31, wherein said antibody or antigen binding fragment thereof comprises an Fc portion that binds an Fcγ RII receptor. 34. The composition of claim 27 or 31, wherein said antibody is an IgG1 antibody or an antigen-binding fragment thereof. 35. The composition of claim 27, or 31, wherein the antigen is a human antigen. 36. The composition of claim 31, wherein the antibody is produced by the hybridoma having ATCC deposit number PTA-1883. 37. A composition suitable for administration to a host for altering immunogenicity of a tumor-associated antigen comprising a complex of CA 125 and a monoclonal antibody produced by the hybridoma having ATCC deposit number PTA-1883 or antigen binding fragment thereof that specifically binds to an epitope of CA 125, wherein administration of the composition to a host results in a multi-epitopic immune response including production of antibodies reactive with at least one other epitope of CA 125.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (18)
Raso Victor ; Paulus Henry, Anti-idiotype vaccines to elicit catalytic antibodies.
Chu Tsann Ming (Williamsville NY) Papsidero Lawrence D. (Orchard Park NY) Croghan Gary A. (Rochester NY), Diagnostic immunoassay methods using monoclonal antibody F36/22 which is specific for human breast carcinoma cells.
Morgan ; Jr. Alton C. (Edmonds WA) Woodhouse Clive S. (Seattle WA) McIntyre Robert F. (Seattle WA), Enhanced production of antibodies utilizing insolubilized immune complexes.
Diamandis Eleftherios P.,CAX ; Redshaw Russell,CAX, Localization and therapy of non-prostatic endocrine cancer with agents directed against prostate specific antigen.
Nudelman Edward (Seattle WA) Singhal Anil (Seattle WA) Clausen Henrik (Seattle WA) Hakomori Sen-itiroh (Seattle WA), Method for the production of monoclonal antibodies directed to tumor-associated gangliosides and fucogangliosides.
Storkus Walter J. ; Lotze Michael T., Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients.
Courtenay-Luck Nigel S. (London GBX), Minimum recognition unit of a PEM mucin tandem repeat specific monoclonal antibody and detection method using same.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.